This course has expired. View available courses.
Oncology
Lung Cancer: Risk Factors, Newly Approved Therapies and the Role of the Pharmacist in Lung Cancer Therapy
The objective of this online program is to help educate and support pharmacists in KSA in understanding the current landscape of lung cancer: genetic mutations, risk factors, and treatment approaches. The module reviews Saudi lung cancer management guidelines, discusses adverse events that may occur with treatment, and Saudi guidelines for the management of these adverse events.
This program is approved for the following professions: Medical Oncology, Thoracic and Cardiac Surgery, Radiation Oncology, Pulmonology, Thoracic Surgery, Pediatric Oncology, Pharmaceutical Sciences, Clinical Pharmacy, Pharmaceutical administration and outcomes, Pharmacy.
DURATION
1 hr
PROFESSION
Pharmacy, Specialist
# OF CREDITS
1.0
ACCREDITATION
SCFHS
EXPIRY DATE
2024-07-27
Recent literature demonstrates that lung cancer represents around 4% of cancers diagnosed cancers in the Kingdom of Saudi Arabia (KSA). It is the 4th most common cancer in men and the 17th most common cancer in women.
The objective of this online program is to help educate and support pharmacists in KSA in understanding the current landscape of lung cancer: genetic mutations, risk factors, and treatment approaches. The module reviews Saudi lung cancer management guidelines, discusses adverse events that may occur with treatment, and Saudi guidelines for the management of these adverse events.
This program is supported by Novartis.
Faculty
Abdul-Rahman Jazieh, MD, MPH
Nora Alkhudair, reviewer
Learning objectives
Upon completion of this continuing education program, participants will be better able to:
- Describe relevant genetic mutations seen in lung cancer
- Outline risk factors and preventive strategies for lung cancer
- Discuss Saudi guidelines for the treatment of lung cancer
- Recognize common adverse events associated with the treatment of lung cancer, especially immune-related adverse events, and implement strategies to mitigate them.
Accreditation
This program is accredited by the Saudi Commission for Health Specialties for 1.0 CPD Hour(s). Activity Accreditation Number: ACA‐20230002494.
Credits are reported to the Saudi Commission for Health Specialties on a monthly basis. Please ensure that your Saudi Commission ID is accurate in your profile and allow sufficient time for credits to appear in your Mustamir account.
This program is approved for the following professions: Medical Oncology, Thoracic and Cardiac Surgery, Radiation Oncology, Pulmonology, Thoracic Surgery, Pediatric Oncology, Pharmaceutical Sciences, Clinical Pharmacy, Pharmaceutical administration and outcomes, Pharmacy.
#
of credits: 1.0
Duration: 1 hr
FAQs & HELP
MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.
All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.
The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
If you are interested in learning more about supporting one of our programs, please contact us.
If you are interested in working with MDBriefCase Group as a writer or committee member, please contact us.
To access the MDBriefCase Group privacy policy, please click here.
No, registration with MDBriefCase is free!
To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.
If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.
Please note: if you submitted multiple password resets, only the link on the most recent email is valid.
You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.
1 hr
Duration
Pharmacy, Specialist
Profession
1.0
# of credits
Learning Objectives
Upon completion of this continuing education program, participants will be better able to:
- Describe
relevant genetic mutations seen in lung cancer - Outline
risk factors and preventive strategies for lung cancer - Discuss
Saudi guidelines for the treatment of lung cancer - Recognize
common adverse events associated with the treatment of lung cancer, especially
immune-related adverse events, and implement strategies to mitigate them.
SCFHS
ACCREDITATION
Oncology
Learning Category
Medication
Topic
0
Price
2024-07-27
Expiry Date
MENA
Region/Language
Course Description
Recent literature demonstrates that lung cancer represents around 4% of cancers diagnosed cancers in the Kingdom of Saudi Arabia (KSA). It is the 4th most common cancer in men and the 17th most common cancer in women.
The objective of this online program is to help educate and support pharmacists in KSA in understanding the current landscape of lung cancer: genetic mutations, risk factors, and treatment approaches. The module reviews Saudi lung cancer management guidelines, discusses adverse events that may occur with treatment, and Saudi guidelines for the management of these adverse events.
This program is supported by Novartis.
Faculty
Abdul-Rahman Jazieh, MD, MPH
Nora Alkhudair, reviewer
Accreditation
This program is accredited by the Saudi Commission for Health Specialties for 1.0 CPD Hour(s). Activity Accreditation Number: ACA‐20230002494.
Credits are reported to the Saudi Commission for Health Specialties on a monthly basis. Please ensure that your Saudi Commission ID is accurate in your profile and allow sufficient time for credits to appear in your Mustamir account.
This program is approved for the following professions: Medical Oncology, Thoracic and Cardiac Surgery, Radiation Oncology, Pulmonology, Thoracic Surgery, Pediatric Oncology, Pharmaceutical Sciences, Clinical Pharmacy, Pharmaceutical administration and outcomes, Pharmacy.
1 hr
Duration
0
Price
1.0
# of credits
